Skip to main content
. 2021 Nov 29;12:781084. doi: 10.3389/fphar.2021.781084

TABLE 1.

Characteristics of the included studies.

Study and year Region and study type Overall no. a Qualitative and quantitative analyses no. b Age (year) Sex (male %) Adenocarcinoma (%) ECOG ≤1% Brain metastasis (%) EGFR common mutation (exon19 del or exon21 L858R) %
30 mg 40 mg 30 mg 40 mg 30 mg 40 mg 30 mg 40 mg 30 mg 40 mg 30 mg 40 mg 30 mg 40 mg
afatinib only
 Arrieta, 2015 (Arrieta et al., 2015) Mexico, prospective cohort study 84 39 26 Overall 59.3 ± 1.6 c Overall 70.2 NA Overall 91.7 NA NA
 Halmos, 2019 (Halmos et al., 2019) Multicenter, prospective cohort study e 228 73 73
 Lim, 2018 (Lim et al., 2018) Taiwan, retrospective cohort study 158 44 114 65.8 (34.3–88.1) d 61.2 (28.1–88.0) d 28.1 41.1 100 100 89.1 94.7 32.8 31.1 68.7 86.8
 Tamura, 2019 (Tamura et al., 2019) Japan, prospective cohort study 1602 70 550 NA 34.5 43.7 NA 76.4 89.1 NA NA
 Tan, 2018 (Tan et al., 2018) Singapore, prospective cohort study 125 23 37 Overall 62 (26–86) d Overall 64 Overall 96.8 NA Overall 33.6 Overall 91.2
 Tanaka, 2018 (Tanaka et al., 2018) Japan, prospective cohort study 15 3 6 Overall 79 (75–87) d Overall 20 Overall 100 Overall 86.7 NA Overall 93.4
 Wang, 2019 (Wang et al., 2019) China, retrospective cohort study 60 19 41 58.1 (44.6–82.7) d 57.2 (36.2–70.9) d 47.4 51.2 100 100 100 100 31.6 43.9 68.4 70.7
 Wei, 2019 (Wei et al., 2019) Taiwan, retrospective cohort study 84 22 62 64.4 ± 12.1 c 58.8 ± 9.7 c 31.6 32.7 100 100 100 94.5 100 100 68.5 89.1
 Yang, 2017 (Yang et al., 2017) Taiwan, retrospective cohort study 48 29 19 67.3 ± 8.0 c 60.6 ± 8.8 c 21 63 100 100 76 84 28 21 100 100
afatinib + 15 mg/ kg bevacizumab
 Ko, 2021 (Ko et al., 2021) Japan, prospective cohort study 16 14 2 Overall 63 (44–73) d Overall 31.25 Overall 100 Overall 100 NA Overall 100
 Ninomiya, 2018 (Ninomiya et al., 2018) Japan, prospective cohort study 19 14 5 67.5 (40–76) d 65.0 (42–68) d 50 60 100 100 100 100 50 40 100 100
afatinib +1 mg sirolimus
 Moran, 2017 (Moran et al., 2017) Spain, prospective cohort study 39 12 4 Overall 58.9 ± 12.3 c Overall 38.5 Overall 84.6 Overall 97.4 NA NA
a

Total number of people involved in the study, including dose groups other than 30 mg or 40 mg.

b

Number of people included in the systematic review.

c

Mean ± standard deviation.

d

Median (range).

e

Before and after self-control study.

NA, Not available.